ExonHit Therapeutics Inc. Extends its License for Ariadne Genomics, Inc. Pathway Studio(R)
ROCKVILLE, MD, September 25, 2007 – Ariadne announced today that ExonHit Therapeutics has extended its license of Pathway Studio. ExonHit uses proprietary technology and Pathway Studio to research alternative RNA splicing in collaboration with drug development partners. ExonHit adoption of Pathway Studio validates the flexibility of the tool to support research in emerging applications.